pancuronium and Myositis

pancuronium has been researched along with Myositis* in 1 studies

Reviews

1 review(s) available for pancuronium and Myositis

Article	Year
Inflammatory and toxic myopathies. Current opinion in neurology and neurosurgery, 1992, Volume: 5, Issue:5 The major advances in the immunopathogenesis and treatment of inflammatory myopathies, and the main criteria that distinguish polymyositis (PM) from dermatomyositis (DM) or inclusion-body myositis (IBM) are presented. The origin and implications of the amyloid and ubiquitin deposits found within the vacuolated fibers of patients with IBM are considered. The pathogenesis of human immunodeficiency virus (HIV) and human T-cell lymphotrophic virus (HTLV)-I-associated PM is presented, and the role of retroviruses in triggering PM, even in the absence of detectable viral genome within the muscle fibers, is discussed. In addition, three toxic myopathies with distinct morphologic, biochemical, or molecular characteristics, caused by zidovudine [azidothymidine (AZT) myopathy], the cholesterol-lowering-agent myopathy (CLAM), and the combination of blocking agents with corticosteroids are presented. Topics: Adrenal Cortex Hormones; Biopsy; Dermatomyositis; Diagnosis, Differential; Humans; Hypolipidemic Agents; Inclusion Bodies; Muscles; Myositis; Pancuronium; Polymyositis; Zidovudine	1992

Article

Year

Current opinion in neurology and neurosurgery, 1992, Volume: 5, Issue:5

The major advances in the immunopathogenesis and treatment of inflammatory myopathies, and the main criteria that distinguish polymyositis (PM) from dermatomyositis (DM) or inclusion-body myositis (IBM) are presented. The origin and implications of the amyloid and ubiquitin deposits found within the vacuolated fibers of patients with IBM are considered. The pathogenesis of human immunodeficiency virus (HIV) and human T-cell lymphotrophic virus (HTLV)-I-associated PM is presented, and the role of retroviruses in triggering PM, even in the absence of detectable viral genome within the muscle fibers, is discussed. In addition, three toxic myopathies with distinct morphologic, biochemical, or molecular characteristics, caused by zidovudine [azidothymidine (AZT) myopathy], the cholesterol-lowering-agent myopathy (CLAM), and the combination of blocking agents with corticosteroids are presented.

Topics: Adrenal Cortex Hormones; Biopsy; Dermatomyositis; Diagnosis, Differential; Humans; Hypolipidemic Agents; Inclusion Bodies; Muscles; Myositis; Pancuronium; Polymyositis; Zidovudine

1992